Affimed NV (NAS:AFMD)
$ 3.85 0.02 (0.52%) Market Cap: 60.37 Mil Enterprise Value: 37.91 Mil PE Ratio: 0 PB Ratio: 1.95 GF Score: 43/100

Q2 2020 Affimed NV Earnings Call Transcript

Aug 11, 2020 / 12:30PM GMT
Release Date Price: $34.7 (-9.87%)
Operator

Good day and welcome to Affimed Second Quarter 2020 Financial Results and Corporate Update Conference Call. (Operator Instructions) As a reminder, today's conference is being recorded. I'd now like to introduce you your host for today's conference, Alexander Fudukidis, Head of Investor Relations at Affimed, please go ahead.

Alexander Fudukidis
Affimed N.V. - Head of IR

Thank you, Charlotte. I'd like to welcome and thank you all for joining us today for Affimed's Second Quarter 2020 Financial Results and Operational Progress Conference Call. Before we begin, I would like to encourage everyone to go to the Investor Relations section of Affimed's website to find the earnings release and related financial tables. We also posted slides on our website that follow our discussion today. On the call today, we are joined by Dr. Adi Hoess, our Chief Executive Officer; Andreas Harstrick, Chief Medical Officer; Arndt Schottelius, Chief Scientific Officer; and Angus Smith, our new Chief Financial Officer, who joined us in July. We are also joined by Dr. Wolfgang Fischer, our

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot